Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Kiadis Pharma april 2019
Volgen
We gaan vandaag vlot door de 11 ben benieuwd of vandaag de 12 ook lukt.
Diekman schreef op 18 april 2019 08:42 :
We gaan vandaag vlot door de 11 ben benieuwd of vandaag de 12 ook lukt.
zou best eens kunnen, ik denk richting de 14 :-)
Volgens mij gaan we vandaag al naar 20 EUR !!! (not)
Alleen jammer dat er binnenkort weer een emissie komt.
Tandsteen schreef op 18 april 2019 09:04 :
Alleen jammer dat er binnenkort weer een emissie komt.
Bij het aantikken van de 12 zou je daar rekening mee moeten houden, ik wel in ieder geval
het verlies dat je maakt met een emissie is peanuts in vergelijking met wat er komt bij goedkeuring
Ortwin schreef op 18 april 2019 09:00 :
Volgens mij gaan we vandaag al naar 20 EUR !!!
(not)
je bent een echte aanwinst voor dit forum
Misschien dat de toekomst uit zal wijzen dat de overname van CytoSen een goede zet is. De koersstijging van gisteren was echter zeer voorbarig:CytoSen heeft nog geen klinische pijplijn. Statistisch gezien is daarmee de kans dat hun therapie ooit de markt haalt kleiner dan 20% Het duurt nog minimaal 4 jaar voordat de CytoSen therapie commercieel vermarkt mag worden En ondertussen kunnen de aandeelhouders van CytoSen meeprofiteren van een eventuele koerswinst van Kiadis bij goedkeuring van Atir101 Verder is het altijd verbazingwekkend dat in de media (bijvoorbeeld het FD) een koopprijs van € 15 miljoen blijft hangen, terwijl de koopprijs in potentie boven de € 100 miljoen uit kan stijgen.
die 10.70 lukt maar niet om voorbij te komen :/
ik kan nergens iets vinden over de cash positie bij CytoSen; website is wel mooi, maar daar houdt het dan wel mee op. Iemand anders die iets meer financiele info. heeft??
StandaardVerlies schreef op 18 april 2019 09:10 :
[...]
je bent een echte aanwinst voor dit forum
Ik doe nochtans gewoon wat de mensen in de posts boven de mijne ook deden...: er gewoon op los fantaseren. Soit, ik heb grote vraagtekens bij de overname. Dit mag toch wel gezegd worden, denk ik? Of moeten we allemaal uitermate positief (of is het naïef) zijn?
Ter info de proof-of-concept voor CSDT002-NK van CytoSen:www.bloodjournal.org/content/early/20...
Harry1977 schreef op 17 april 2019 21:07 :
[...]
Ik hoop het, maar hoezo denk je dat?
omdat Ampligen in de wolken leeft :)))))
@AD, Vergeet niet dat het risico van de prijs ook ingedamd is dmv prestatiebeloningen. Mocht het middel een succes blijken, dan heeft Kiadis een tweede middel die ze gecombineerd kunnen gebruiken met het eigen ATIR. De investering is het dan zeker waard, aangezien ze op dezelfde markt bijna fungeren en ze met deze overname ook ingangen bij Amerikaanse ziekenhuizen hebben. Maar eens, als ATIR goedgekeurd is en het aandeel is over 2 jaar(na lockup) €25 waard is, is het een overname van €200 milj. Investeren is risico nemen, ik vind het zelf een goede zet maar gelukkig zijn er ook andere meningen.
En nog een artikel over de overname: Kiadis is set to buy CytoSen Therapeutics to expand into anti-cancer natural killer (NK) cell therapies. The all-stock transaction will give Kiadis control of a preclinical NK cell therapy and see it add CAR-T pioneer Carl June to its scientific advisory board. Dutch biotech Kiadis has focused its efforts to date on T cell therapies, specifically a drug designed to improve outcomes in cancer patients who undergo partially matched, haploidentical hematopoietic stem cell transplants (HSCT). That drug, ATIR101, could come to market in Europe later this year and is on the road to the phase 3 data needed to win global approvals. With ATIR101 potentially closing in on the end of clinical development, Kiadis is set to add another asset to its pipeline by acquiring CytoSen for 1.94 million shares upfront. Kiadis trades at around €10 ($11) a share. CytoSen has spent the past few years working on NK cell technology licensed from the University of Central Florida. Using a nanoparticle processing technology, CytoSen thinks it can improve the expansion and activation of NK cells, thereby facilitating multiple high-dose infusions with potent anti-cancer effects. The goal is to augment a patient’s innate immunity to wipe out cancer cells, either as a monotherapy or in combination with T cells that dial up the adaptive immune response. “I believe the fields of NK cells and T cells are enormously synergistic and the combination could potentially help patients with devastating diseases,” the University of Pennsylvania’s Carl June said in a statement. June, a scientific adviser to CytoSen, will join Kiadis’ scientific advisory board when the deal closes. Stefan Ciurea and Dean Lee, co-founders of CytoSen, demonstrated the potential of NK cell therapy in proof-of-concept work performed with their colleagues at MD Anderson Cancer Center. NK cells were given in conjunction with haploidentical HSCT to 13 leukemia patients. One of the patients relapsed, resulting in a relapse rate the authors called “remarkably low.” CytoSen set out to build on the findings by holding a pre-IND meeting with the FDA last year ahead of a planned phase 2 trial of its lead NK program, CSDT002-NK, in high-risk acute myeloid leukemia or myelodysplastic syndrome patients undergoing haploidentical HSCT. At one point, that trial was due to get underway in the first half of this year, but Kiadis is aiming toward a 2020 start date. By then, Kiadis may have won approval for ATIR101 in Europe and could be about a year away from generating the phase 3 data it needs to support filings in the U.S. and other regions. The CytoSen deal provides Kiadis with a fairly low-risk way to gain a backup to ATIR101 and set the stage for possible combinations of NK and T cell therapies. Kiadis will absorb the $6 million in cash held by CytoSen when it closes the deal, partly offsetting the upfront stock costs. And it will pay milestones tied to six clinical development and regulatory events using 5.82 million shares, at most.
KaPeeN63 schreef op 18 april 2019 09:21 :
ik kan nergens iets vinden over de cash positie bij CytoSen; website is wel mooi, maar daar houdt het dan wel mee op.
Iemand anders die iets meer financiele info. heeft??
www.iex.nl/Nieuws/ANP-170419-078/Kiad... 6 milj dollar
En bij deze nog een kritisch artikel aangaande de overname: Kiadis moves to reduce reliance on its in-house lead Jacob Plieth Perhaps sensing trouble ahead Kiadis diversifies beyond ATIR101 by buying Cytosen, but it is a scientific appointment that will cause real excitement. Given Molmed’s problems in trying to sell Zalmoxis, a product for averting stem cell transplant complications, it is understandable that Kiadis should try to diversify beyond its competing offering, ATIR101. However, it is debatable whether Cytosen Therapeutics, which Kiadis bought this morning, holds the answer. Cytosen is a specialist in natural killer (NK) cell therapeutics, an area that has promised much and delivered virtually nothing so far. Perhaps investors will be much more excited about the fact that, as part of the deal, the cell therapy pioneer Dr Carl June is joining the combined company’s scientific advisory board. Dr June and his colleagues at the University of Pennsylvania were the scientific originators of Novartis’s Kymriah, the first CAR-T therapy to secure US approval. He does not appear to have been involved with Cytosen before, and will be seen as providing a strong endorsement of the combined company. Coup His appointment is quite a coup, given the documented problems of NK cell therapeutics. Ziopharm and Nantkwest are two groups that have talked up the potential of NK cells transduced to express CAR constructs, but they have stalled clinically. One problem is NK cells’ plasticity, meaning that their phenotype is relatively unstable and their function unpredictable; it is also debatable whether they can be frozen and thawed efficiently, making the prospect of commercial manufacturing very problematic. Perhaps this is where Cytosen comes in: the group claims to have discovered and patented a method of using nanoparticle-bound 4-1BBL and IL-21 to stimulate and expand NK cells. This, it says, enables production at highly potent and therapeutically effective dosages. Its lead asset using this technology is coded CSTD002, and is this year supposed to start phase II as a treatment for AML relapse in high-risk post-transplant patients. This is based on the results of early clinical work carried out at MD Anderson Cancer Center. Cytosen is a private, virtually operating company that was incorporated in Florida five years ago. Another advantage for Kiadis is that its acquisition will not cost it anything: the takeover is structured as an all-stock move worth 1.94m Kiadis shares now, followed by up to 5.82m based on future milestones. A valid question is why, if Cytosen’s technology holds such promise, the company could not apparently raise the cash it needed from venture capitalists, thus remaining independent. Diversification Cytosen should provide a welcome diversification away from Kiadis's ATIR101, and on an investor call today Kiadis said it had been looking for an acquisition target for the past year. ATIR101 is a procedure that allows stem cell transplantation to take place when only a haploidentical – half-matched – but not fully matched donor is available. It is awaiting EU approval, though the CHMP’s decision on it has been put back. Particularly worrying is the precedent set by Molmed, whose Zalmoxis has failed to generate significant sales since being launched for the same use, and this fact has also unnerved investors in Bellicum, whose EU filing for the Rivo-cel procedure has been delayed (Is Molmed the canary in Bellicum and Kiadis’s coalmine?, July 31, 2018). Kiadis will now have a chance to show that NK cells do, after all, have commercial potential. Among other NK cell players, Nantkwest has managed to start clinical trials of a product based on the disputed NK-92 cell line, while clinical CAR-NK work is being advanced by MD Anderson and Chinese groups like Persongen and Allife Medical Science. Nantkwest had promised to start clinical trials of CAR-NK cells targeting CD19 and Her2 in 2016, but its investors are still waiting.
Een nieuwe spike komt eraan...
@Tronald, bedankt voor het delen van deze artikelen maar kun je een link plaatsen naar deze 2 artikelen. Alvast bedankt.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
870,27
-0,43%
EUR/USD
1,0734
+0,34%
FTSE 100
8.078,86
+0,48%
Germany40^
17.916,40
-0,95%
Gold spot
2.330,69
+0,63%
NY-Nasdaq Composite
15.712,75
+0,10%
Stijgers
Dalers